These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 25658389)

  • 21. Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report.
    Igawa T; Fushimi S; Matsuo R; Ikeda F; Nouso K; Yoshino T; Nakatsukasa H
    Clin J Gastroenterol; 2014 Oct; 7(5):465-70. PubMed ID: 26184030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation.
    Guillouche P; Féray C
    Aliment Pharmacol Ther; 2011 Jan; 33(2):163-74. PubMed ID: 21083593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic hepatitis C virus infection: a review for pharmacists.
    Rodis J
    J Am Pharm Assoc (2003); 2007; 47(4):508-20; quiz 508-20. PubMed ID: 17616500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status of treatment for chronic hepatitis C virus infection.
    Talwani R; Gilliam BL; Rizza SA; Nehra V; Temesgen Z
    Drugs Today (Barc); 2012 Mar; 48(3):219-31. PubMed ID: 22462041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-containing and interferon-free HCV therapy for HIV-infected patients.
    Sulkowski MS
    Semin Liver Dis; 2014 Feb; 34(1):72-8. PubMed ID: 24782260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-combination strategies for the treatment of chronic hepatitis C.
    Aronsohn A; Jensen D
    Semin Liver Dis; 2014 Feb; 34(1):30-6. PubMed ID: 24782256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New hepatitis C therapies: the toolbox, strategies, and challenges.
    Pawlotsky JM
    Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapeutic approaches for hepatitis C.
    Au JS; Pockros PJ
    Clin Pharmacol Ther; 2014 Jan; 95(1):78-88. PubMed ID: 24126682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
    Fabrizi F; Martin P; Messa P
    Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nationwide survey of specialist knowledge on current standard of care (Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China.
    Wei L; Li J; Yang X; Wang G; Feng B; Hou J; Duan Z; Jia J; Ren H; Niu J; Chen X; Wang FS; Shang J; Bo Q; Li R; Liu Y; Zhuang H
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1995-2003. PubMed ID: 27043040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus infection and immunomodulatory therapies.
    Forde KA; Reddy KR
    Clin Liver Dis; 2009 Aug; 13(3):391-401. PubMed ID: 19628156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014.
    Yao X; Sangaralingham LR; Ross JS; Shah ND; Talwalkar JA
    Am J Manag Care; 2016 Jun; 22(6):e224-32. PubMed ID: 27355910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.
    Larrubia JR; Moreno-Cubero E; Miquel J; Sanz-de-Villalobos E
    World J Gastroenterol; 2015 Mar; 21(12):3480-91. PubMed ID: 25834312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on hepatitis C: epidemiology, treatment and resistance to antiviral therapies.
    Ness E; Kowdley KV
    Minerva Gastroenterol Dietol; 2015 Sep; 61(3):145-58. PubMed ID: 25990619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.